Cancer name Glioblastoma Multiforme
Cancer Type GBM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment S3I201
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature PGAM1
Official Symbol PGAM1
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description We examined expression of PGAM1 in U87 and U373 cells and TPI1 in U87, LN18 and LN229 cells in response to S3I201 (68 μM) treatment. PGAM1 was found with increased expressions on S3I201 treatment as also observed in iTRAQ analysis while no significant alteration was observed for TPI1.
PMID 27565396
Title Proteomic level changes associated with S3I201 treated U87 glioma cells